Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
PolyPid Ltd. (PYPD)
:PYPD
Holding PYPD?
Track your performance easily
Earnings Data
Report Date
Feb 05, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.88Last Year’s EPS
-3.97Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 11, 2020
|% Change Since: -5.71%
|Next Earnings Date:Aug 19, 2020
Earnings Call Sentiment|Positive
The call highlighted significant advancements in the SHIELD II trial and a strong financial position but also noted increased net loss and high R&D expenses. The positive developments in trial enrollment and financial positioning suggest a promising outlook for the company's lead product, D-PLEX100.Company Guidance
During the PolyPid third quarter 2024 earnings call, several key metrics and guidance points were discussed. The company is making significant strides in the SHIELD II trial for their D-PLEX100 product, having enrolled approximately 550 out of a planned 630 subjects across 60 centers worldwide. This trial aims to prevent surgical site infections, and the unblinded interim analysis results are expected within the current quarter. Financially, PolyPid reported a cash runway into the first quarter of 2025, supported by $9.5 million in cash and potential additional funding of up to $24.6 million if certain conditions from their pipe financings are met. R&D expenses increased to $6 million, reflecting the trial's accelerated enrollment, contributing to a net loss of $7.8 million for the quarter. Looking ahead, the company anticipates completing patient enrollment by December and sharing top-line results in the upcoming quarter, with an eye on potential regulatory submission in 2026.Acceleration in SHIELD II Trial Enrollment
Significant progress in the SHIELD II trial for D-PLEX100, with enrollment of approximately 550 subjects and a substantial ramp-up in recruitment, enrolling more than 80 subjects per month since the end of summer.
Strong Financial Position
PolyPid is funded beyond the upcoming interim analysis and into 2026 if all warrants are exercised in their recent private placements.
Positive SHIELD I Results Published
SHIELD I Phase III trial results, which showed statistically significant improvements, were published in the International Journal of Surgery, supporting the execution of SHIELD II.
---
PYPD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
PYPD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 13, 2024 | $3.50 | $3.40 | -2.86% |
| Aug 14, 2024 | $3.56 | $3.49 | -1.97% |
| May 08, 2024 | $4.86 | $4.31 | -11.32% |
| Feb 14, 2024 | $6.79 | $6.23 | -8.25% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does PolyPid Ltd. (PYPD) report earnings?
PolyPid Ltd. (PYPD) is schdueled to report earning on Feb 05, 2025, TBA Not Confirmed.
What is PolyPid Ltd. (PYPD) earnings time?
PolyPid Ltd. (PYPD) earnings time is at Feb 05, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PYPD EPS forecast?
PYPD EPS forecast for the fiscal quarter 2024 (Q4) is -0.88.
---